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http://www.biomedcentral.com/1471-2407/14/681RESEARCH ARTICLE Open AccessA-770041 reverses paclitaxel and doxorubicin
resistance in osteosarcoma cells
Zhenfeng Duan1*, Jianming Zhang2, Shunan Ye1, Jacson Shen1, Edwin Choy1, Gregory Cote1, David Harmon1,
Henry Mankin1, Yingqi Hua3, Yu Zhang4, Nathanael S Gray5 and Francis J Hornicek1Abstract
Background: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational
oncologists. In the last few decades, significant effort has been made to search for inhibitors to reverse MDR by
targeting ATP-binding cassette (ABC) transporters (Pgp, MRP) directly, but these efforts have achieved little clinical
success. Protein kinases play important roles in many aspects of tumor cell growth and survival. Combinations of
kinase inhibitors and chemotherapeutics have been observed to overcome cancer drug resistance in certain
circumstances.
Methods: We screened a kinase specific inhibitor compound library in human osteosarcoma MDR cell lines to
identify inhibitors that were capable of reversing chemoresistance to doxorubicin and paclitaxel.
Results: We identified 18 small molecules that significantly increase chemotherapy drug-induced cell death in
human osteosarcoma MDR cell lines U-2OSMR and KHOSR2. We identified A-770041 as one of the most effective
MDR reversing agents when combined with doxorubicin or paclitaxel. A-770041 is a potent Src family kinase
(Lck and Src) inhibitor. Western blot analysis revealed A-770041 inhibits both Src and Lck activation and expression.
Inhibition of Src expression in U-2OSMR and KHOSR2 cell lines using lentiviral shRNA also resulted in increased
doxorubicin and paclitaxel drug sensitivity. A-770041 increases the intracellular drug accumulation as demonstrated
by calcein AM assay.
Conclusions: These results indicate that small molecule inhibitor A-770041 may function to reverse ABCB1/
Pgp-mediated chemotherapy drug resistance. Combination of Src family kinase inhibitor with regular
chemotherapy drug could be clinically effective in MDR osteosarcoma.
Keywords: Osteosarcoma, MDR, Src kinase, DoxorubicinBackground
Osteosarcoma, the most common primary malignant
tumor of bone, is typically treated with surgery and adju-
vant chemotherapy [1,2]. Chemotherapy usually includes
a combination of methotrexate, doxorubicin, and cisplatin.
Unfortunately, the efficacy of these agents is hampered by
the eventual development of multidrug resistance (MDR).
This plateau in terms of overall survival has been present
for a few decades without change. Almost one third of pa-
tients with localized osteosarcoma experience recurrent or
progressive disease (usually caused by drug resistance)* Correspondence: zduan@mgh.harvard.edu
1Center for Sarcoma and Connective Tissue Oncology, Massachusetts General
Hospital, 100 Blossom St., Jackson 1115, Boston 02114, MA, USA
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unless otherwise stated.and the average survival period after a recurrence are
about one year [1-3]. Therefore, overcoming MDR has
been a high priority for both clinical and investigational
oncologists [4-6]. Unfortunately, the mechanism of ac-
quiring MDR in osteosarcoma is not well understood. A
variety of mechanisms, including overexpression of the
ABC drug efflux pumps P-glycoprotein (Pgp), and eleva-
tion of the apoptotic threshold that contributes to drug re-
sistance [5,7-12], have been proposed to play important
roles for cancers acquiring MDR. Targeting multidrug re-
sistance is one of the biggest challenges for successful
treatment of osteosarcoma.
The human kinome contains approximately 600-protein
kinases that mediate phosphorylation of proteins at an es-
timated 250,000 sites [13,14]. Multiple lines of evidencetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pathways and multidrug resistant in different cancers. Sev-
eral kinases such as IGF-1R, PI3K/AKT, PDGFR, mTOR
and Src have been found to be highly expressed in differ-
ent osteosarcomas, particularly in the late stage of the de-
velopment of drug resistant tumor [15-17]. Inhibition of
AKT enhances the cytotoxic effects of both paclitaxel and
doxorubicin in tumor model systems [18]. Small interfer-
ing RNA (siRNA) downregulation of IGF-IR expression in
MDR osteosarcoma cell lines also causes resensitization to
doxorubicin [19,20]. It has been shown that suppression
of several kinases, such as PI3K/AKT/mTOR, Src, IGF-R,
EGFR, JIK, Jak, or MEK/ERK significantly enhance cell
death in the presence of low concentrations of chemother-
apeutic drug, suggesting the potential utility of these ki-
nases as drug targets [5,13,15,19,21]. Recently, some
kinase inhibitors have also been found to reverse MDR by
inhibiting the function of ABC transporters, including Pgp
or MRP, or enhancing the efficacy of conventional chemo-
therapeutic drugs induced apoptosis [22,23].
Based on these observations, it is anticipated that kinases
represent a class of potential therapeutic targets in chemo-
therapy resistant osteosarcoma. We hypothesized that inhi-
biting of the expression and activation of certain kinases
may enhance the efficacy of chemotherapy and/or reverse
MDR. In order to identify the most suitable kinase candi-
dates as therapeutic targets in drug resistant osteosarcoma
patients, we screened a well-annotated kinase inhibitor fo-
cused library comprised of 3,000 commercially available
known kinase inhibitors, as well as novel, ATP competitive
kinase inhibitors targeting either active or inactive kinase
conformations [24]. We systematically evaluated the po-
tential reversal of MDR by the identified agent A-770041
and further studied the underlying mechanisms.
Methods
Kinase inhibitor library
We assembled a library of approximately 3000 diverse in-
hibitors and screened a subset of the library for kinome-
wide selectivity profiling using binding (KinomeScan) [25],
enzymatic (SelectScreen, Invitrogen Carlsbad, CA) and
chemical proteomic approaches (Kinativ) [26]. This library
is comprised of 500 commercially available known kinase in-
hibitors, as well as novel ATP competitive kinase inhibitors
targeting either active or inactive kinase conformations. These
compounds are characterized as being relatively potent and
selective toward a relatively narrow array of kinase targets.
This library was then screened against a number of different
cancer cell lines or cells engineered to be associated with a
defined oncogene (BRFV600E, KRAS, c-Myc, etc.) [27,28].
Human osteosarcoma cell lines
The multidrug resistant U-2OSMR (established by selec-
tion against doxorubicin) and U-2OSTR (established byselection against taxol/paclitaxel) was established in our
laboratory as previously reported [20,23]. The multidrug
resistant KHOSR2 (established by selection with doxorubi-
cin) cell line was kindly provided by Dr. Efstathios Gonos
(Institute of Biological Research and Biotechnology,
Athens, Greece) [29]. These cell lines were cultured in
RPMI 1640 (Invitrogen, CA) supplemented with 10% FBS,
100 units/mL penicillin, and 100 μg/mL streptomycin
(Invitrogen). Cells were incubated at 37°C in 5% CO2-95%
air atmosphere and passaged when near-confluent mono-
layers were achieved using trypsin-EDTA solution. Drug
resistant cell lines were periodically cultured in the re-
spective drug to confirm their drug resistance characteris-
tics. Cells were free from Mycoplasma contamination as
tested using the MycoAlert Mycoplasma Detection Kit
from Cambrex (East Rutherford, NJ).
Drugs
Doxorubicin and paclitaxel were provided by the phar-
macy at the Massachusetts General Hospital Cancer
Center. The stock solutions of drugs were prepared ac-
cording to the manufacturer’s specifications and stored
at −20°C.
Screening kinase inhibitor focused library
We screened the kinase specific compound library in
human osteosarcoma MDR cell lines U-2OSMR and
KHOSR2 to determine the role of kinases in supporting
chemoresistance to doxorubicin and paclitaxel in these
MDR cells. The kinase inhibitor screening was per-
formed at the concentration of 0.66 μM and 1.8 μM with
or without the presence of paclitaxel (0.1 μM), doxorubi-
cin (0.5 μM) in a four-day cellular proliferation assay
(Figure 1). The combinatory drug effect was measured
via CellTiter-Glo® Luminescent Cell Viability Assay Kit
(Promega, Madison, WI) for automated high-throughput
screening (HTS), cell proliferation and cytotoxicity
assays.
MTT cell proliferation assay
Drug cytotoxicity was assessed in vitro using the MTT
assay as previously described [15,23]. Briefly, 2 × 103 cells
per well were plated in 96-well plates in culture medium
(RPMI 1640 supplemented with 10% FBS and penicillin/
streptomycin) containing increasing concentrations of
either A-770041, doxorubicin, paclitaxel alone or in
combination with both. After 96 h of culture, 20 μL of
MTT (5 mg/mL in PBS, purchased from Sigma) were
added to each well and the plates were incubated for
4 h. The resulting formazan product was dissolved with
acid (HCL)-isopropanol and the absorbance at a wave-
length of 490 nm (A490) was read on a SPECTRAmax
Microplate Spectrophotometer (Molecular Devices).
Experiments were done in triplicate. Dose–response
Figure 1 Strategy for screening a kinase specific compound library in multidrug resistant osteosarcoma cell lines. The kinase inhibitor
screening was performed at the concentration of 0.66 μM and 1.8 μM with or without the presence of paclitaxel (0.1 μM) or doxorubicin (0.5 μM)
in a four-day cellular proliferation assay. The combinatory drug effect was measured via CellTiter-Glo® Luminescent Cell Viability Assay Kit
as described in Methods. Red: no effect on drug sensitivities; green: minor effect on drug sensitivities; blue: significant effect on
drug sensitivities.
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(GraphPad Software).
Lentiviral Src kinase shRNA transduction
The effect of Src kinase knockdown on drug sensitivity
in osteosarcoma MDR cell lines U-2OSMR and KHOSR2
was examined using MISSION® LentiExpress™ human
Src kinases shRNA (Sigma, St Louis, MO, TRC number:
TRCN0000038149, Target sequence: 5′-GCTCGGCTCA
TTGAAGACAAT −3″). Transduction was carried out
by following the manufacturer’s protocol as previously
described [30]. In brief, on day 1, U-2OSMR or KHOSR2
cells were diluted to 2 × 104cells/ml in complete medium.
Polybrene (hexadimethrine bromide) was added to a final
concentration of 11.3 μg/ml and then 90 μl of cell suspen-
sion was added to each well of a 96-well plate following by
add 10 μl of Src kinases shRNA lentivirus solution and
incubated overnight. On day 2, the media was gently aspi-
rated and 100 μl of complete media with different concen-
trations of paclitaxel or doxorubicin were replaced in eachwell. On day 5, the number of viable cells was determined
by MTTassay as described above.
Western blotting
The human phosphorylated Lck (pLck), pSrc, pAKT
(threonine [Thr]308), pmTOR, CDK11, survivin, and
BcL-XL antibodies were purchased from Cell Signaling
Technologies (Dedham, MA). The Pgp monoclonal anti-
body C219 was purchased from Covance Inc. (Formerly
Signet, Dedham, MA). The mouse monoclonal anti-
body to human actin was purchased from Sigma-Aldrich
(St. Louis, MO). Western blot analysis was performed as
previously described with modifications [30]. Briefly, the
cells were lysed in 1X radioimmunoprecipitation assay
(RIPA) lysis buffer (Upstate Biotechnology, Lake Placid,
NY), and protein concentration was determined by the DC
Protein Assay (Bio-Rad, Hercules, CA) with a spectropho-
tometer (Beckman DU-640, Beckman Instruments, Inc.).
Total protein (25 μg) was resolved on NuPage 4% to 12%
Bis-Tris gels (Invitrogen). After electrophoresis, proteins
Duan et al. BMC Cancer 2014, 14:681 Page 4 of 11
http://www.biomedcentral.com/1471-2407/14/681were transferred to PROTRAN® nitrocellulose transfer
membranes (Whatman GmbH, Germany). Membranes
were blocked for 2 hours at 4°C with Odyssey Blocking
Buffer (LI-COR Biosciences, Lincoln, NE), then incubated
at 4°C overnight with primary antibodies diluted in Odyssey
Blocking Buffer. After incubating with primary antibodies,
the membranes were washed with TBS-T (containing 0.1%
Tween 20) three times for 5 minutes. The membranes were
then incubated with IRDye800CW-conjugated goat anti-
rabbit IgG or IRDye680-conjugated goat anti-mouse
IgG secondary antibodies (LI-COR Biosciences) diluted in
Odyssey Blocking Buffer for 1 hour at room temperature
with shaking. The blots were then washed three times
with TBS-T and rinsed again with PBS. The levels of
expressed proteins were visualized by scanning the mem-
brane on an Odyssey Infrared Imaging System (LI-COR
Biosciences) with both 680- and 800-nm channels.
Apoptosis assay
Apoptosis was evaluated by a caspase-cleaved keratin 18
based quantification kit, the M30-Apoptosense ELISA
assay, as per manufacturer’s instructions (Peviva AB,
Bromma, Sweden). The ELISA apoptosis detects a 21-kDa
fragment of cytokeratin 18 that is only revealed after cas-
pase cleavage of the protein. Osteosarcoma MDR cells of
U-2OSMR and KHOSR2 were seeded at 8 × 10
3 cells/per
well in a 96-well plate for 24 hours before being treated
with 0.1 μM doxorubicin plus different concentrations of
A-770041 for 48 hours. The cells were then lysed by add-
ing 10 μl 10% NP-40 per well, and the manufacturer’s in-
structions for the apoptosis assay were followed. Apoptosis
was also evaluated by Western blot using whole-cell lysates
immunoblotted with specific antibodies to PARP (Cell
Signaling Technologies) and its cleavage products.
Intracellular accumulation of calcein AM
Osteosarcoma MDR cells of KHOSR2 were plated onto
96-well plates at a density of 4 × 103 cells/well in a volume
of 100 μl RPMI1640 medium and grown for 24 h. Differ-
ent concentrations (0, 0.1, 0.5 and 1 μM) of A-770041
were added for one hour. Calcein AM (Invitrogen) was di-
luted to 1 μM in culture medium, and then 50 μl of cal-
cein AM was added to each microplate well containing
100 μl of the culture medium. After 30 minutes of expos-
ure to calcein AM at 37°C, the medium was removed by
aspiration, and cells were counterstained with Hoechst
33342 (1 μg/ml in culture medium) for 2 min. The intra-
cellular accumulation of calcein AM was then visualized
and quantified on a Nikon Eclipse Ti-U fluorescence
microscope equipped with a SPOT RT digital camera.
Statistical analysis
Statistical analyses were performed using the GraphPad
PRISM5 software from GraphPad Software, Inc (SanDiego, CA, USA). The student t test was used to analyze
the differences between two groups. Results are expressed
as mean ± SD and P < 0.05 was considered statistically
significant.
Results
Identification of kinase inhibitors that reverse drug
resistance in osteosarcoma MDR cell lines
After screening 3,000 compounds from a preselected,
kinase-based small molecule library, we identified 18 small
molecule compounds that can significantly increase
chemotherapy drug-induced cell death in human osteosar-
coma cell lines U-2OSMR and KHOSR2 (Additional file 1:
Table S1). Several previously reported kinase inhibitors
such as dasatinib, AP25434, GSK461364, GP74514A and
JNK-IN-X were also on the list of 18 small molecule com-
pounds. We further verified efficacy of those 18 lead
compounds by serially titrating drug combination studies
with doxorubicin and paclitaxel. Eight of them showed
improved IC50 in combination with doxorubicin or pacli-
taxel. These 8 small molecule compounds include inhibi-
tors targeting multiple pan-tyrosine kinases such as Src
family kinase (A-770041), kinases in cell cycle regulations
such as PLK1 (GSK461364), CDK (GP74514A), and ki-
nases in cell stress responses such as JNK (JNK-IN-X).
Further studies validated A-770041, a compound previ-
ously reported as a highly potent pan-Src family kinase in-
hibitor [31-33], as the top one of the most effective MDR
reversing agents when used in combination with doxo-
rubicin or paclitaxel, as determined by drug sensitivity as-
says. Because of their target specificity and wide range
coverage of the human kinome, the kinase inhibitor fo-
cused library compounds were anticipated to be useful to
more easily identify the kinase mediators of cancer cell
survival associated signaling that could be exploited for
the purpose of drug development. Identified drug candi-
dates could ideally provide further insight into the mech-
anism(s) involved in cancer MDR development, and at the
same time potentially aid in developing and optimizing
novel small molecule inhibitors able to overcome drug re-
sistance and kill cancer cells more effectively.
Structure of A-770041 and its activities reversing drug
resistance
A-770041 was reported as an inhibitor Lck, a Src-family
kinase expressed in lymphocytes [31,32]. We examined
the effect of A-770041 on increasing the chemotherapy
sensitivities of osteosarcoma MDR cell lines. After ex-
posing the U-2OSMR or KHOSR2 cell lines to paclitaxel,
doxorubicin, or A-770041 alone, or the combination of
paclitaxel or doxorubicin with A-770041 in complete cell
culture medium for 96 hours, the relative numbers of vi-
able cells were determined by MTT assay. Incubation of
both U-2OSMR and KHOSR2 cell lines with nonlethal
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crease paclitaxel and doxorubicin drug sensitivities and
reverse drug resistance (Figure 2).
Effects on drug sensitivities from inhibiting Src
expression by shRNA
A-770041 is known as a Src-family kinase inhibitor. To
evaluate the contribution of Src mRNA expression levels
to drug resistance in osteosarcoma MDR cell lines, the
Src expression in U-2OSMR or KHOSR2 cells was inhib-
ited by using lentiviral Src kinase shRNA. The relative
paclitaxel or doxorubicin sensitivities were determined
by MTT in Src shRNA-transduced and in control MDR
cell lines. Cytotoxicity was measured 96 hours after
transduction with Src shRNA and treatment with pacli-
taxel or doxorubicin (see Methods). The results showed
that Src down-regulation by shRNA partially recovered
sensitivity to paclitaxel and doxorubicin (Figure 2B and
Figure 2C).
A-770041 is synergistic with paclitaxel and doxorubicin in
KHOSR2 cell lines with ABCB1/Pgp overexpression
The potential reversal of MDR by A-770041 was further
evaluated in KHOSR2 cell lines with defined overexpres-
sion of the major MDR transporter ABCB1/Pgp. This
MDR osteosarcoma cell line is remarkably resistant to
the corresponding transporter substrate anticancer drugs
including paclitaxel and doxorubicin. Subsequently, theFigure 2 A-770041 or Src shRNA reverses drug resistance. (A) Structur
resistance inU-2OSMR cell line. (C) A-770041 or Src lentiviral shRNA reverse
mean ± standard deviations (SD).synergistic effects of combinations of A-770041 with
paclitaxel or doxorubicin in different ratios were evalu-
ated in KHOSR2 cell lines. Synergistic cytotoxic effects
were found in combinations of A-770041 with paclitaxel
or doxorubicin in KHOSR2 MDR cell lines (Figure 3).
The sensitivity to A-770041 was also tested in a panel of
non MDR osteosarcoma cell lines including U-2OS,
KHOS, SaoS, MG63 cell lines. A-770041 alone was
found to exhibit similar anticancer activity in these drug
sensitive cell lines as in drug resistant U-2OSMR or
KHOSR2 cell lines (data not shown).
Effect of A-770041 on the expression and activation of
Src, Lck
Src kinase expression and activation has been shown as the
primary pathway involved in the malignant osteosarcoma
phenotype [34,35]. The effects of A-770041 on the expres-
sion of pSrc, pLck, pAKT and other kinases or apoptotic
proteins in osteosarcoma MDR cell lines were analyzed by
Western blot. The U-2OSMR, KHOSR2 or U-2OSTR cell
lines were incubated either with a range of concentrations
(0, 0.3 or 1 μM) of A-770041 for 48 hours. Western blot
analysis revealed that A-770041 inhibits both Src and Lck
activation and expression in osteosarcoma MDR cells, but
has less or no effect on other kinases such as pAKT,
pmTOR or CDK11 (Figure 4). Treatment with A-770041
also decreased expression of the antiapoptotic proteins sur-
vivin and Bcl-XL in the U-2OSMR cell line (Figure 4).e of A-770041. (B) A-770041 or Src lentiviral shRNA reverse paclitaxel
doxorubicin resistance in KHOSR2 cell line. Results are expressed as
Figure 3 Synergistic effect of A-770041 with paclitaxel or doxorubicin in drug resistant cell line. The KHOSR2 cells were cultured in the
presence of varying concentrations of either paclitaxel (0.0004–1 μM, A) or doxorubicin (0.004–10 μM, B) alone or in combination with A-770041
(0.004–10 μM) in regular RPMI1640 medium for 96 hours. The inhibition of cell growth was determined by MTT assay. The results are shown as
the mean value of triplicate samples and are representative of 3 independent experiments. The student t test was used to analyze the differences
between two groups. *P < 0.01 vs. paclitaxel or A-770041 treated cells alone, #P < 0.001 vs. paclitaxel or A-770041 treated cells alone.
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of Pgp-mediated paclitaxel and doxorubicin resistance
Since the combination of A-770041 with paclitaxel or
doxorubicin is highly synergistic (Figure 3), we also in-
vestigated whether A-770041 possesses properties other
than Pgp inhibition to reverse Pgp-mediated resistance.
The U-2OSMR or KHOSR2 cell lines were treated with
a combination of low concentration of doxorubicin
(0.1 μM) and A-770041 (0.3 μM, 1 μM) for 48 hours,
after which the extent of apoptosis was measured.
While doxorubicin only led to insignificant apoptosis at
this low concentration, its combination with A-770041
was found to dramatically increase the apoptosis in the re-
sistant U-2OSMR or KHOSR2 cells as demonstrated by
M30-Apoptosense ELISA assay (Figure 5A). The effect of
A-770041 on the induction of apoptosis was further inves-
tigated by immunoblotting for PARP cleavage. PARP
cleavage was detected after the treatment of U-2OSMR or
KHOSR2 cells with A-770041 in combination with doxo-
rubicin (Figure 5B). In addition to PARP cleavage assay,
quantification of apoptosis was also evaluated by checking
Caspase-3/7 activations. Compared with cells treated with
doxorubicin alone, the combination of A-770041 resulted
in greater levels of apoptosis in these osteosarcoma MDR
cell lines (data not shown). The reversal of Pgp-mediateddrug resistance by A-770041 may also be associated
with alteration of the transporter expression. Therefore,
protein expression of Pgp was examined in U-2OSMR,
KHOSR2 and U-2OSTR cells. After incubating the cells
with A-770041 at concentrations up to 1 μM for 48 hours,
A-770041 did not alter the expression of Pgp protein
levels (Figure 5B).
A-770041 modulates Pgp-mediated uptake and efflux of
calcein AM
Reversing Pgp-mediated MDR will result in an intracellular
accumulation of chemotherapeutics, which can be achieved
by inhibiting Pgp function. Therefore, we examined the ef-
fect of A-770041 on the uptake and efflux of Calcein AM, a
substrate of Pgp in KHOSR2. Pgp inhibition can be directly
correlated with the amount of intracellular Calcein AM
fluorescence. A-770041 was shown to increase intracellular
accumulation of Calcein in osteosarcoma MDR cell line
KHOSR2 in a dose-dependent manner as determined by
image analysis (Figure 6). A-770041 had a prominent effect
on the accumulation of Calcein in KHOSR2 cells at a con-
centration as low as 0.01 μM. In the control parental
drug-sensitive cell lines U-2OS and KHOS, which do not
overexpress Pgp, A-770041 had no evident effect on accu-
mulation of Calcein (data not shown).
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Figure 4 A-770041 inhibits Src and Lck expression in drug-resistant osteosarcoma cells in a dose-dependent manner. U-2OSMR, KHOSR2
or U-2OSTR cells were treated with A-770041 (0, 0.3, or 1 μM ) in regular RPMI1640 medium for 48 hours. Total cellular proteins were subjected to
Western blotting with specific antibodies as described in Methods. The levels of expressed proteins were visualized by scanning the membrane
on an Odyssey Infrared Imaging System. Arrows indicate the confirmation of A-770041 inhibits both Src and Lck activation and expression as
determined by densitometric analysis of Western blot results.
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Figure 5 A-770041 enhances apoptosis induced by doxorubicin in drug resistant osteosarcoma cells. (A) U-2OSMR, KHOSR2 or U-2OSTR cells were
seeded at 8 × 103 cells/per well in a 96-well plate for 24 hours before being treated with 0.1 μM doxorubicin plus different concentrations of A-770041 for
48 hours. The cells were lysed with 10% NP40, and the M30-Apoptosense ELISA assay was done as described in Methods. Results are expressed as mean±
SD. The student t test was used to analyze the differences between two groups. *P < 0.01 vs. doxorubicin treated cells alone, # P < 0.001 vs. doxorubicin
treated cells alone. (B) Apoptosis was also evaluated by Western blot using whole-cell lysates immunoblotted with specific antibodies to PARP.
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Figure 6 Fluorescent images of dose-dependent increase in intracellular accumulation of calcein AM in KHOSR2 following 30 min
treatment with A-770041. The calcein AM assay was optimized and performed using the Vybrant Multidrug Resistance kit in KHOSR2 cells.
Cells were plated onto 96-well plates at a density of 4 × 103 cells/well in a volume of 100 μl RPMI1640 medium and grown for 24 h. Different
concentrations (0, 0.01, 0.1 and 0.5 μM) of A-770041 were added for one hour. 50 μl of calcein AM were added to each well. After 30 minutes
exposure to calcein AM at 37°C, cells were counterstained with Hoechst 33342 for 2 min. The cell fluorescence images were acquired by a
fluorescence microscope.
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Protein kinases play important roles in the many aspects
of cancer including in maintaining or supporting the drug
resistance phenotype [13,22,23]. Overexpression and acti-
vation of specific kinases have been associated with pro-
gressive drug resistance. Several recent reports have
demonstrated that some kinase inhibitors or other agents
are also potent inhibitors of Pgp or MRP transporters and
thereby increase drug sensitivities [22,23,36-39]. Synergis-
tic cytotoxic effects of inorganic phosphate and chemo-
therapeutic drugs on human osteosarcoma cells have been
reported recently [38,39]. Small molecular compounds
capable of inhibiting specific kinases and Pgp represent a
desirable approach for overcoming Pgp-mediated drug
resistance in human cancer. In this study, we report that
A-770041, a known Src family kinase inhibitor originally
developed as an immunosuppressant to prevent acute
graft rejection [31-33], is a novel MDR reversing agent
whose mechanism of action includes both the inhibition
of Src and Lck activation and expression, and the inhib-
ition of Pgp function by increases the intracellular drug
accumulation.
Cell-based screening of a preselected kinase-based small
molecule compound library identified A-770041 as one of
the most effective drug resistance reversing agents in
two osteosarcoma MDR cell line models, U-2OSMR andKHOSR2, having defined overexpression of the major
MDR transporters, ABCB1/Pgp. These osteosarcoma re-
sistant cell lines have been extensively characterized with
stable MDR phenotype in previous studies [6,7,20,29].
MTT assay showed A-770041 significantly overcomes
drug resistance in both U-2OSMR and KHOSR2 MDR cell
lines. Knockdown of Src with lentiviral shRNA also in-
creased drug sensitivity to transporter substrate anticancer
drugs paclitaxel and doxorubicin, suggesting that blocking
the Src pathway might overcome MDR in osteosarcoma.
We then evaluated A-770041’s potential synergistic cyto-
toxic effect when used in combination with paclitaxel and
doxorubicin. The data showed that A-770041 is highly
synergistic with both paclitaxel and doxorubicin in these
MDR cell lines. As demonstrated by Western analysis,
part of these effects was potentially through decreased ex-
pression of Src and Lck.
Src is a nonreceptor tyrosine kinase encoded by the Src
proto-oncogene. It is one of the eight members (Src, Fyn,
Yes, Lck, Lyn, Hck, Fgr and Blk) of the Src family of ki-
nases. Both overexpression and overactivation of Src have
been shown to aid in the development of osteosarcoma by
promoting key oncogenic mechanisms such as cell prolif-
eration, adhesion, invasion, and resistance to apoptosis
induced by chemotherapy drugs [34,40,41]. Src kinase
activity is regulated via a variety of receptor and non-
Duan et al. BMC Cancer 2014, 14:681 Page 9 of 11
http://www.biomedcentral.com/1471-2407/14/681receptor tyrosine kinases such as EGFR, PDGF, and Jak.
Activation of Src kinase leads in turn to activation of a
variety of downstream signaling pathways such as the Ras/
MAPK pathway, and activation of the Stat3, resulting in
cell cycle progression from G2 to M phase and VEGF pro-
duction, which aids in angiogenesis and tumor growth
and invasion. Src is highly expressed and activated in sar-
comas of diverse subtypes, including high-grade osteosar-
coma, leiomyosarcoma, synovial sarcoma and liposarcoma
[34,40]. The Src inhibitor dasatinib (BMS-354825) induces
apoptosis in osteosarcoma cells [35]. A more recent study
showed treatment of synovial sarcoma cells with dasatinib
also led to apoptosis, decreased proliferation, and was as-
sociated with reduced phosphorylation of IGF-1R, AKT
and Stat3. Furthermore, combination treatment with dasa-
tinib and chemotherapeutic agents results in additive ef-
fects [40]. Inhibition of Src protein expression by small
interfering RNA also induced apoptosis [35]. Inhibition of
Src and its downstream signaling pathways has been
shown to inhibit growth, migration, and invasion of a var-
iety of human cancer cells including osteosarcoma [35,42].
It has been shown that inhibition of Src, either pharmaco-
logically by Src inhibitor or through expression of a Src
dominant-negative fusion construct, increased the cyto-
toxicity of paclitaxel or cisplatin, in both mouse and hu-
man cancer cells [21,40,42]. Importantly, Src inhibition
has also been shown to reverse drug resistance in ovarian
cancer MDR cells [42]. Cytotoxicity in response to Src in-
hibition was associated with enhanced apoptosis in these
studies. Consistent with these findings, A-770041 also in-
creased the apoptosis induced by doxorubicin in osteosar-
coma MDR cell lines. The synergistic activity of A-770041
with doxorubicin suggests that A-770041 could induce
apoptosis in doxorubicin-resistant cells through mecha-
nisms independent of inhibition of Pgp.
The interaction of kinase inhibitor with ABC trans-
porter Pgp has been documented in several studies. For
example, gefitinib (Iressa), a selective EGFR tyrosine kin-
ase inhibitor, is used for the treatment of lung cancer. It
has been found that clinically achievable levels of gefi-
tinib moderately reversed the Pgp-mediated resistance to
paclitaxel and docetaxel in Pgp overexpressing cells [43].
Gefitinib increased the intracellular accumulation of the
Pgp substrate rhodamine-123 in resistant cells, and acti-
vated ATPase in a preparation of pure Pgp-expressing
membrane [43,44]. These findings suggest that gefitinib
may directly interact with Pgp and inhibit its function.
Our current study showed A-770041 significantly increases
intracellular accumulation of calcein in osteosarcoma
MDR cell line KHOSR2 in a dose-dependent manner.
These results indicated that A-770041 can also inhibit Pgp
efflux function via interaction with Pgp. Drugs interacting
with MDR transporter proteins like Pgp may be useful not
only for the reversal of cancer drug resistance, but also forincreasing the absorption or the brain entry of various
pharmacological agents [22].
In summary, we found that A-770041 could increase
the sensitivity of drug-resistant osteosarcoma cells to
various cytotoxic chemotherapeutic agents (doxorubicin,
paclitaxel). These studies provided a proof of principle
that A-770041 is active against osteosarcoma cell lines
with known resistance to conventional anticancer agents,
as well as primary tumor cells from osteosarcoma patients.
Further in vivo research is warranted to understand the
implication of A-770041 in overcoming drug resistance.
Conclusions
Kinases play an essential role in cancer cell growth, sur-
vival and drug resistance, and these enzymes are actively
investigated by the pharmaceutical industry to create
molecular therapies.
In this study, a cell-based screening assay using the
MDR osteosarcoma cell line was used to screen a kinase
specific inhibitor compound library and identify small-
molecule compounds capable of reversing MDR. We
identified A-770041, a potent Src family kinase (Lck and
Src) inhibitor, as one of the most effective MDR revers-
ing agents when combined with doxorubicin or pacli-
taxel. Because osteosarcoma is characterized by frequent
relapse that is associated with the development of MDR,
these findings provide support for further development
of A-770041 or its derivates as candidate inhibitors of
MDR in osteosarcoma treatment.
Additional file
Additional file 1: Identification of 18 kinase inhibitors that reverse
drug resistance in osteosarcoma MDR cell lines.
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